By JESSICA DaMASSSA, WTF HEALTH
Acorai is an early-stage medical device startup working with Bayer to improve the way we manage the world’s 65 million patients living with heart failure by using their own smart phones. CEO Filip Peters shows the Acorai device, which is basically an extended smart phone case packed with four different kinds of sensor technologies that work together to measure the pressure inside a patient’s heart, by simply holding their phone against their chest. Of course, the real magic is the algorithm that turns these readings into early detection of a potential incident. How does this stack up against the status-quo way we’re currently caring for these types of patients? Filip says that, right now, the alternative for such monitoring is an IMPLANTED sensor, which many patients aren’t even able to get. As a result, most of the early warning signs of impending heart failure are missed; Acorai’s tech has the potential to be truly revolutionary as it’s able to detect the signs that lead to heart failure hospitalizations up to 30 days in advance.
Acorai has been selected as one of four “Growth Track” companies in Bayer G4A’s Digital Health Partnerships Program, and Filip talks to us about the potential Bayer sees in the daily data stream of information Acorai’s device makes available to cardiologists. A fascinating look at the future of cardiac care!
